X
Please Wait
Applying Filters...
1. 1,3-benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1r-trans)-
2. Epidiolex
1. 13956-29-1
2. (-)-cannabidiol
3. (-)-trans-cannabidiol
4. Epidiolex
5. Cbd
6. (-)-cbd
7. Gwp42003-p
8. Cannabidiol [usan]
9. (-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
10. Delta1(2)-trans-cannabidiol
11. 2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
12. 19gbj60sn5
13. Chembl190461
14. 3556-78-3
15. .delta.1(2)-trans-cannabidiol
16. Chebi:69478
17. Btx-1204
18. Btx-1503
19. Gwp42003
20. Gwp-42003-p
21. Gwp-42003
22. Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (-)-(e)-
23. 2-[1r-3-methyl-6r-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
24. C21h30o2
25. 1,3-benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1r-trans)-
26. 2-((1r,6r)-6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
27. (1'r,2'r)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol
28. Cannabidiol Solution
29. 2-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
30. (-)-cannabidiol (cbd)
31. Cannabidiolum
32. Unii-19gbj60sn5
33. 1,3-benzenediol, 2-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-
34. 1,3-benzenediol, 2-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, (1r-trans)-
35. Epidiolex (tn)
36. 1,3-benzenediol, 2-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-
37. P0t
38. Cannabidiol (7ci)
39. Cardiolrx
40. (+/-)-cannabidiol
41. Cannabidiol [mi]
42. Cannabidiol [inn]
43. Cannabidiol (usan/inn)
44. D1(2)-trans-cannabidiol
45. Cannabidiol [inci]
46. Cannabidiol [mart.]
47. Cannabidiol [usp-rs]
48. Cannabidiol [who-dd]
49. (-)-cannabidiol (synthetic)
50. Schembl119679
51. Gtpl4150
52. Zyn002
53. 2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol #
54. 2-(6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
55. Delta(1(2))-trans-cannabidiol
56. Cannabidiol [orange Book]
57. Dtxsid00871959
58. Dtxsid301038839
59. Zinc4097406
60. Bdbm50121429
61. Bdbm50318484
62. Cannabidiol Solution [usp-rs]
63. Akos032948358
64. Db09061
65. Ncgc00386518-01
66. (-)-cannabidiol 1.0 Mg/ml In Methanol
67. Ac-34022
68. Db-093531
69. Sativex (cbd + Thc, Fixed-dose Oral Spray)
70. C07578
71. D10915
72. Nabiximols (cbd + Thc, Fixed-dose Oral Spray)
73. Q422917
74. (-)-cannabidiol (cbd) 100 Microg/ml In Methanol
75. (-)-cannabidiol (cbd) 1000 Microg/ml In Methanol
76. (-)-cannabidiol (cbd) 250 Microg/ml In Acetonitrile
77. (3r,4r)-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
78. Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, (+-)-
79. Resorcinol, 2-p-mentha-1,8-dien-3-yl-5-pentyl-, Trans-(-)- (8ci)
80. 1,3-benzenediol, 2-(4-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, Trans-
81. 2-((1r,6r)-3-methyl-6-(1-methylethenyl)cyclohex-2-enyl)-5-pentylbenzene-1,3-diol
82. 2-(3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
83. 2-(4-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Trans-
84. 2-(6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol (cannabidiol)
85. 2-[(1r,6r)-3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl]-5-pentylbenzene-1,3-diol
86. 2-[3-methyl-6-(methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
87. Cannabidiol Solution, ~10 Mg/ml In Ethanol, Analytical Standard, For Drug Analysis
88. Cannabidiol Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
89. Cannabidiol Solution, 1.0 Mg/ml In Methanol, Analytical Standard, For Drug Analysis
90. (1'r,2'r)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-2,6-diol
91. (1'r,2'r)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro[1,1'-biphenyl]-2,6-diol
92. 2-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-5-pentylbenzene-1,3-diol
| Molecular Weight | 314.5 g/mol |
|---|---|
| Molecular Formula | C21H30O2 |
| XLogP3 | 6.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 6 |
| Exact Mass | 314.224580195 g/mol |
| Monoisotopic Mass | 314.224580195 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 414 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications: 1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy; Due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications: 1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; 2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Treatment of Rett syndrome
Treatment of seizures associated with Dravet Syndrome (DS), Treatment of seizures associated with infantile spasms (IS), Treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Treatment of seizures associated with Tuberous Sclerosis Complex (TSC)
Although the exact mechanism and magnitude of effects of THC and CBD are not fully understood, CBD has been shown to have analgesic, anticonvulsant, muscle relaxant, anxiolytic, neuroprotective, anti-oxidant, and anti-psychotic activity. This wide variety of effects is likely due to it's complex pharmacological mechanisms. In addition to binding to CB1 and CB2 receptors of the endocannabinoid system, there is evidence that CBD activates 5-HT1A serotonergic and TRPV12 vanilloid receptors, antagonizes alpha-1 adrenergic and -opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH).
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AX
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX24 - Cannabidiol
Absorption
Following a single buccal administration, maximum plasma concentrations of both CBD and THC typically occur within two to four hours. When administered buccally, blood levels of THC and other cannabinoids are lower compared with inhalation of smoked cannabis. The resultant concentrations in the blood are lower than those obtained by inhaling the same dose because absorption is slower, redistribution into fatty tissues is rapid and additionally some of the THC undergoes hepatic first pass metabolism to 11-OH-THC, a psycho-active metabolite. The CBD component of sublingual Sativex was found to have a Tmax of 1.63hr and a Cmax of 2.50ng/mL, while buccal Sativex was found to have a Tmax of 2.80hr and a Cmax of 3.02ng/mL.
Route of Elimination
Elimination from plasma is bi-exponential with an initial half-life of one to two hours. The terminal elimination half-lives are of the order of 24 to 36 hours or longer. Sativex is excreted in the urine and faeces.
Volume of Distribution
Cannabinoids are distributed throughout the body; they are highly lipid soluble and accumulate in fatty tissue. The release of cannabinoids from fatty tissue is responsible for the prolonged terminal elimination half-life.
THC and CBD are metabolized in the liver by a number of cytochrome P450 isoenzymes, including CYP2C9, CYP2C19, CYP2D6 and CYP3A4. They may be stored for as long as four weeks in the fatty tissues from which they are slowly released at sub-therapeutic levels back into the blood stream and metabolized via the renal and biliary systems. The main primary metabolite of CBD is 7-hydroxy-cannabidiol.
The CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.
The exact mechanism of action of CBD and THC is not currently fully understood. However, it is known that CBD acts on cannabinoid (CB) receptors of the endocannabinoid system, which are found in numerous areas of the body, including the peripheral and central nervous systems, including the brain. The endocannabinoid system regulates many physiological responses of the body including pain, memory, appetite, and mood. More specifically, CB1 receptors can be found within the pain pathways of the brain and spinal cord where they may affect CBD-induced analgesia and anxiolysis, and CB2 receptors have an effect on immune cells, where they may affect CBD-induced anti-inflammatory processes. CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body. Allosteric regulation of a receptor is achieved through the modulation of the activity of a receptor on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects.
Market Place
